PE20051095A1 - DERIVADOS 1H-TIENO[2,3-c] PIRAZOL UTILES COMO INHIBIDORES DE QUINASA - Google Patents
DERIVADOS 1H-TIENO[2,3-c] PIRAZOL UTILES COMO INHIBIDORES DE QUINASAInfo
- Publication number
- PE20051095A1 PE20051095A1 PE2005000121A PE2005000121A PE20051095A1 PE 20051095 A1 PE20051095 A1 PE 20051095A1 PE 2005000121 A PE2005000121 A PE 2005000121A PE 2005000121 A PE2005000121 A PE 2005000121A PE 20051095 A1 PE20051095 A1 PE 20051095A1
- Authority
- PE
- Peru
- Prior art keywords
- ilbenzoil
- carboxamide
- amino
- pirazole
- alkyl
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 1-METHYL-1-PHENYLETHYL Chemical class 0.000 abstract 2
- BNYCHCAYYYRJSH-UHFFFAOYSA-N 1h-pyrazole-5-carboxamide Chemical compound NC(=O)C1=CC=NN1 BNYCHCAYYYRJSH-UHFFFAOYSA-N 0.000 abstract 2
- 102000003989 Aurora kinases Human genes 0.000 abstract 1
- 108090000433 Aurora kinases Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE 1H-TIENO[2,3-c]PIRAZOL DE FORMULA (I); EN DONDE R ES ARILO O HETEROARILO OPCIONALMENTE SUSTITUIDO; R1 Y R2 SON, INDEPENDIENTEMENTE ENTRE SI, H, ALQUILO(C1-C3) LINEAL O RAMIFICADO, -CONH2, CH2NR'R" O JUNTOS CON EL ATOMO DE C AL QUE ESTAN UNIDOS FORMAN CICLOALQUILO(C3-C6); R' Y R" SON INDEPENDIENTEMENTE H, ALQUILO(C1-C3), O JUNTOS CON EL N AL QUE ESTAN UNIDOS PUEDEN FORMAR ANILLO HETEROCICLICO COMO PIRROLIDINIL-1-IL, AZETIDINIL-1-ILO, ENTRE OTROS; R3 ES H, HALOGENO, -OH, CIANO, ALQUILO(C1-C3) LINEAL O RAMIFICADO O ALCOXI(C1-C6). SON COMPUESTOS PREFERIDOS: N(1-METIL-1-FENILETIL)-3-[(4-MORFOLIN-4-ILBENZOIL)AMINO]-1H-TIENO[2,3-C]PIRAZOL-5-CARBOXAMIDA, 3-[(4-MORFOLIN-4-ILBENZOIL)AMINO]-N-(1-FENILCICLOPROPIL)-1H-TIENO[2,3-C] PIRAZOL-5-CARBOXAMIDA, N-[(1R)-1-(FLUOROFENIL)ETIL]-3-[(4-MORFOLIN-4-ILBENZOIL)AMINO]-1H-TIENO[2,3-C]PIRAZOL-5-CARBOXAMIDA. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCESO DE ELABORACION. ESTOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA QUINASA, PARTICULARMENTE DE AURORA QUINASA, POR LO QUE SON UTILES EN EL TRATAMIENTO DE CANCER Y TRANSTORNOS DE PROLIFERACION CELULAR
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54145204P | 2004-02-03 | 2004-02-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20051095A1 true PE20051095A1 (es) | 2005-12-31 |
Family
ID=34837492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000121A PE20051095A1 (es) | 2004-02-03 | 2005-02-02 | DERIVADOS 1H-TIENO[2,3-c] PIRAZOL UTILES COMO INHIBIDORES DE QUINASA |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US8138217B2 (es) |
| EP (1) | EP1711177B1 (es) |
| JP (1) | JP4908233B2 (es) |
| KR (1) | KR20060124734A (es) |
| CN (1) | CN1946395B (es) |
| AP (1) | AP2006003701A0 (es) |
| AR (1) | AR047531A1 (es) |
| AT (1) | ATE396724T1 (es) |
| AU (1) | AU2005210114B2 (es) |
| BR (1) | BRPI0507375A (es) |
| CA (1) | CA2555262C (es) |
| CR (1) | CR8546A (es) |
| CY (1) | CY1108246T1 (es) |
| DE (1) | DE602005007181D1 (es) |
| DK (1) | DK1711177T3 (es) |
| DO (1) | DOP2005000014A (es) |
| EA (1) | EA011032B1 (es) |
| EC (1) | ECSP066767A (es) |
| ES (1) | ES2307144T3 (es) |
| GE (1) | GEP20094633B (es) |
| GT (1) | GT200500020A (es) |
| IL (1) | IL177141A0 (es) |
| MA (1) | MA28429B1 (es) |
| MX (1) | MXPA06008787A (es) |
| NO (1) | NO20063768L (es) |
| NZ (1) | NZ548896A (es) |
| PA (1) | PA8622801A1 (es) |
| PE (1) | PE20051095A1 (es) |
| PL (1) | PL1711177T3 (es) |
| PT (1) | PT1711177E (es) |
| SI (1) | SI1711177T1 (es) |
| TN (1) | TNSN06244A1 (es) |
| TW (1) | TW200526204A (es) |
| UA (1) | UA86223C2 (es) |
| UY (1) | UY28738A1 (es) |
| WO (1) | WO2005074922A1 (es) |
| ZA (1) | ZA200606179B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004013146A1 (en) * | 2002-07-25 | 2004-02-12 | Pharmacia Italia S.P.A | Condensed heterocyclic pyrazole derivatives as kinase inhibitors |
| WO2007009898A1 (en) * | 2005-07-19 | 2007-01-25 | Nerviano Medical Sciences S.R.L. | 1h-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors |
| AU2006298563A1 (en) * | 2005-10-06 | 2007-04-12 | Merck & Co., Inc. | Use of fused pyrrole carboxylic acids for the treatment of neurodegenerative and psychiatric diseases as D-amino acid oxidase inhibitors |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| WO2007113198A2 (en) * | 2006-03-30 | 2007-10-11 | Nerviano Medical Sciences S.R.L. | Use of a kinase inhibitor for the treatment of particular resistant tumors |
| WO2007138017A1 (en) * | 2006-05-31 | 2007-12-06 | Nerviano Medical Sciences S.R.L. | 1h-furo[3,2-c] pyrazole compounds useful as kinase inhibitors |
| FR2904626B1 (fr) * | 2006-08-03 | 2008-09-19 | Sanofi Aventis | Derives de pyrazolo[4,3]thiazole, leur preparation et leur application en therapeutique |
| GEP20135728B (en) | 2006-10-09 | 2013-01-25 | Takeda Pharmaceuticals Co | Kinase inhibitors |
| KR100923540B1 (ko) | 2007-11-23 | 2009-10-27 | 한국과학기술연구원 | 5-아실하이드라진카르보닐-3,4-디치환 피라졸 유도체 및이의 제조방법 |
| AR071780A1 (es) * | 2008-05-15 | 2010-07-14 | Nerviano Medical Sciences Srl | Derivados de carbamoilo de carbonilamino-pirazoles biciclicos como profarmacos |
| JP2012521429A (ja) * | 2009-03-23 | 2012-09-13 | メルク・シャープ・エンド・ドーム・コーポレイション | 疼痛治療用のｐ２ｘ３受容体アンタゴニスト |
| US9255072B2 (en) | 2011-03-04 | 2016-02-09 | National Health Rsearch Institutes | Pyrazole compounds and thiazole compounds as protein kinases inhibitors |
| HUE060655T2 (hu) * | 2012-04-05 | 2023-04-28 | Nerviano Medical Sciences Srl | Új alkilálási reagens |
| WO2019024809A1 (zh) * | 2017-08-01 | 2019-02-07 | 正大天晴药业集团股份有限公司 | 作为RORγ抑制剂的双环化合物 |
| IL274963B2 (en) * | 2017-11-30 | 2024-10-01 | Hanmi Pharmaceutical Co Ltd | THIENO[3,2-d]PYRIMIDINE COMPOUND HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE |
| CN113072562B (zh) * | 2021-04-06 | 2022-01-14 | 山东大学 | 一种GSK-3β抑制剂及其制备方法与应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0234622B1 (en) | 1986-02-19 | 1990-06-27 | Duphar International Research B.V | New thio compounds having fungicidal activity |
| GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| PL353455A1 (en) | 1999-08-12 | 2003-11-17 | Pharmacia Italia S.P.A. | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| DE60143041D1 (de) * | 2000-08-10 | 2010-10-21 | Pfizer Italia Srl | Bizyklische pyrazole wirksam als kinase inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen |
| JP2004517840A (ja) | 2000-11-27 | 2004-06-17 | フアルマシア・イタリア・エツセ・ピー・アー | フェニルアセトアミド−ピラゾール誘導体およびそれの抗腫瘍薬としての使用 |
| CA2434066A1 (en) | 2001-01-26 | 2002-09-12 | Pharmacia Italia S.P.A. | Chromane derivatives, process for their preparation and their use as antitumor agents |
| PL368347A1 (en) | 2001-09-26 | 2005-03-21 | Pharmacia Italia S.P.A. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| JP4751063B2 (ja) * | 2002-05-17 | 2011-08-17 | ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ | キナーゼ阻害剤として活性のアミノインダゾール誘導体、それらの調製方法、及びそれらを含む薬学的組成物 |
| MXPA05000629A (es) * | 2002-07-17 | 2005-04-25 | Pharmacia Italia Spa | Derivados de pirazol heterobiciclico como inhibidores de cinasa. |
| WO2004013146A1 (en) * | 2002-07-25 | 2004-02-12 | Pharmacia Italia S.P.A | Condensed heterocyclic pyrazole derivatives as kinase inhibitors |
| US20050026984A1 (en) * | 2003-07-29 | 2005-02-03 | Aventis Pharma S.A. | Substituted thieno [2,3-c] pyrazoles and their use as medicinal products |
-
2005
- 2005-01-28 TW TW094102761A patent/TW200526204A/zh unknown
- 2005-02-02 PT PT05701307T patent/PT1711177E/pt unknown
- 2005-02-02 JP JP2006551790A patent/JP4908233B2/ja not_active Expired - Fee Related
- 2005-02-02 PL PL05701307T patent/PL1711177T3/pl unknown
- 2005-02-02 PE PE2005000121A patent/PE20051095A1/es not_active Application Discontinuation
- 2005-02-02 SI SI200530297T patent/SI1711177T1/sl unknown
- 2005-02-02 CA CA2555262A patent/CA2555262C/en not_active Expired - Fee Related
- 2005-02-02 EA EA200601418A patent/EA011032B1/ru not_active IP Right Cessation
- 2005-02-02 ES ES05701307T patent/ES2307144T3/es not_active Expired - Lifetime
- 2005-02-02 BR BRPI0507375-8A patent/BRPI0507375A/pt not_active IP Right Cessation
- 2005-02-02 EP EP05701307A patent/EP1711177B1/en not_active Expired - Lifetime
- 2005-02-02 NZ NZ548896A patent/NZ548896A/en unknown
- 2005-02-02 UA UAA200609515A patent/UA86223C2/uk unknown
- 2005-02-02 GE GEAP20059600A patent/GEP20094633B/en unknown
- 2005-02-02 DO DO2005000014A patent/DOP2005000014A/es unknown
- 2005-02-02 CN CN200580005922.0A patent/CN1946395B/zh not_active Expired - Fee Related
- 2005-02-02 KR KR1020067017754A patent/KR20060124734A/ko not_active Ceased
- 2005-02-02 DE DE602005007181T patent/DE602005007181D1/de not_active Expired - Lifetime
- 2005-02-02 DK DK05701307T patent/DK1711177T3/da active
- 2005-02-02 WO PCT/EP2005/001021 patent/WO2005074922A1/en not_active Ceased
- 2005-02-02 AU AU2005210114A patent/AU2005210114B2/en not_active Ceased
- 2005-02-02 AP AP2006003701A patent/AP2006003701A0/xx unknown
- 2005-02-02 AR ARP050100399A patent/AR047531A1/es not_active Application Discontinuation
- 2005-02-02 AT AT05701307T patent/ATE396724T1/de active
- 2005-02-02 MX MXPA06008787A patent/MXPA06008787A/es active IP Right Grant
- 2005-02-03 UY UY28738A patent/UY28738A1/es not_active Application Discontinuation
- 2005-02-03 US US11/050,360 patent/US8138217B2/en not_active Expired - Fee Related
- 2005-02-03 PA PA20058622801A patent/PA8622801A1/es unknown
- 2005-02-03 GT GT200500020A patent/GT200500020A/es unknown
-
2006
- 2006-07-26 ZA ZA200606179A patent/ZA200606179B/xx unknown
- 2006-07-27 IL IL177141A patent/IL177141A0/en unknown
- 2006-08-03 TN TNP2006000244A patent/TNSN06244A1/fr unknown
- 2006-08-03 CR CR8546A patent/CR8546A/es not_active Application Discontinuation
- 2006-08-03 MA MA29227A patent/MA28429B1/fr unknown
- 2006-08-10 EC EC2006006767A patent/ECSP066767A/es unknown
- 2006-08-23 NO NO20063768A patent/NO20063768L/no not_active Application Discontinuation
-
2008
- 2008-08-07 CY CY20081100834T patent/CY1108246T1/el unknown
-
2012
- 2012-02-24 US US13/404,697 patent/US8481584B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20051095A1 (es) | DERIVADOS 1H-TIENO[2,3-c] PIRAZOL UTILES COMO INHIBIDORES DE QUINASA | |
| PE20060361A1 (es) | Compuestos heterociclicos como inhibidores de la cinesina mitotica | |
| PE20080677A1 (es) | Inhibidores de pirrolotriazina cinaza | |
| PE20060599A1 (es) | DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1 | |
| DE60316013D1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
| TW200519096A (en) | Quinazoline analogs as receptor tyrosine kinase inhibitors | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| PE20060777A1 (es) | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas | |
| PE20050081A1 (es) | Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas | |
| ATE490253T1 (de) | Synthese von 5-substituierten 7-azaindolen und 7- azaindolinen | |
| PE20080059A1 (es) | Quinazolinas para la inhibicion de pdk1 | |
| BRPI0413233A (pt) | novos compostos | |
| PE20091376A1 (es) | Derivados de fenilamino como moduladores de beta-amiloide | |
| PE20060664A1 (es) | Amidas biciclicas como inhibidores de cinasa | |
| TW200732329A (en) | Aryl-isoxazolo-4-yl-oxadiazole derivatives | |
| TNSN07196A1 (en) | Potentiators of glutamate receptors | |
| PE20120034A1 (es) | Compuestos derivados de n-fenilpirimidin-2-amina | |
| ATE554087T1 (de) | Neue kinaseinhibitoren | |
| MX2007003603A (es) | Metodos para preparar compuestos de indazol. | |
| DE602004011924D1 (de) | Chinazoline derivate und ihre anwendung in der krebsbehandlung | |
| PE20081496A1 (es) | Derivados de 2,5-dihidro-3-h-pirazolo[4,3-c]piridazin-3-ona sustituidos como antagonistas de los receptores cb1 | |
| PE20071090A1 (es) | 5-pirazolpiperidinas-(sustituidas) | |
| EA200501595A1 (ru) | Азабициклические производные в качестве антагонистов мускаринового рецептора | |
| EA200600071A1 (ru) | Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором | |
| PE20081492A1 (es) | Derivados de sulfonamida heterociclicos como antagonista de edg-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |